New therapeutic options in non-small-cell lung cancer have been available through a great
in-depth and genomic research, improving preclinical disease patterns and identifying the …

Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Over the last decade, systemic cancer therapies have evolved to exploit the growing
knowledge of molecular aberrations involved in the development and progression of lung …

Non-small cell lung cancer (NSCLC) is one of the most lethal malignancies accountings for
nearly 80% of all lung cancer cases diagnosed and causing over one million deaths …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …

In this review, the authors aim to provide an overview of current molecular targeted therapies
for NSCLC, to propose an algorithm for clinical application of presently available treatment …

The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

Lung cancer is the leading cause of cancer-related death among men and women in the
United States. Approximately 80-85% of lung cancer cases are non–small-cell lung cancer …

Lung cancer remains the leading cause of malignancy-related deaths in the USA,
regardless of advances in therapeutic agents. Non-small-cell lung cancer demonstrates …

Although tumor molecular-profile-directed therapy appears promising in early clinical
studies, there are many practical challenges to its successful clinical application in non …